Research Desk Line-up: Cellect Biotech Post Earnings Coverage
LONDON, UK / ACCESSWIRE / September 14, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Sage Therapeutics, Inc. (NASDAQ: SAGE), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=SAGE. The Cambridge based Company announced on September 12, 2017, that top-line results from its Phase-3 STATUS Trial of brexanolone (SAGE-547) in the treatment super-refractory status epilepticus (SRSE) indicate that the Company has failed to meet the main goal, comparing success in weaning of third-line agents and resolution of potentially life-threatening status epilepticus with brexanolone versus placebo, when added to standard-of-care. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Cellect Biotechnology Ltd. (NASDAQ: APOP) for due-diligence and potential coverage as the Company provided on August 21, 2017, its financial results for Q2 2017 which ended on June 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Cellect Biotech when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on SAGE; also brushing on APOP. Go directly to your stock of interest and access today's free coverage at:
- The STATUS Trial was conducted under a Special Protocol Assessment (SPA) agreement with the US Food and Drug Administration (FDA).
- The trial was designed to evaluate the efficacy and safety of brexanolonein patients with SRSE, aged two years or older, in the US, Canada, and Europe.
- In the double-blind trial, 132 patients were randomized to receive either brexanolone or placebo in addition to standard-of-care third-line anti-seizure agents for six days.
- Patients who failed to respond to brexanolone or placebo were subsequently eligible for an open-label infusion of brexanolone at a higher dose over a 6-day period.
Trial helped in Understanding GABA Mechanisms Thoroughly
Jeff Jonas, M.D., Chief Executive Officer of Sage Therapeutics, said that he is proud of the Sage team for making a significant progress in understanding how to best treat critically ill patients. He added that although the Company did not meet the primary endpoint, this first-ever trial in a highly variable and complex patient population confirms that research in a critical care unit is possible and deepens the understanding of GABA mechanisms and their effect on brain circuitry.
Trial Represents a Significant Contribution to SRSE Research
Eric Rosenthal, M.D., Co-Principal Investigator of the STATUS Trial, stated that SRSE is an extremely complicated condition to treat and there is a significant unmet need for new treatments. He added that a lot has been learned from the STATUS Trial, that represents a significant contribution to SRSE research and he hopes these data will provide a foundation for the development of future treatments for patients with this devastating condition.
Findings of the STATUS Trial
- 43.9% patients treated with brexanolone and 42.4% patients treated with placebo successfully weaned from third-line agents during the double-blind period.
- Secondary endpoint results were found to be consistent with the primary endpoint.
- 37% patients treated with open-label brexanolone achieved treatment response, post double-blind period
- Almost all patients experienced adverse events that were similar between the two treatment groups.
About Super-refractory Status Epilepticus
Status epilepticus (SE) is when a seizure lasts longer than 5 minutes or when seizures occur close together and the person does not recover between seizures. An SE patient is first treated with benzodiazepines, and if no response, is then treated with other, second-line, anti-seizure drugs. SRSE is a medical emergency in which patients experience continuous seizures that do not stop even after standard treatment attempts in the ICU have not been effective in controlling the ongoing seizure. There are no treatments for SRSE currently approved by FDA.
About Brexanolone (SAGE-547)
Brexanolone is an allosteric modulator of both synaptic and extrasynaptic GABAA receptors. Brexanolone is an intravenous agent that was evaluated as an adjunctive therapy for the treatment of SRSE in the global Phase-3 STATUS Trial. Brexanolone is also being developed for the treatment of postpartum depression (PPD).
Last Close Stock Review
Sage Therapeutics' share price finished yesterday's trading session at $70.37, sliding 7.89%. A total volume of 2.95 million shares have exchanged hands, which was higher than the 3-month average volume of 467.08 thousand shares. The Company's stock price skyrocketed 1.16% in the past six months and 71.30% in the previous twelve months. Additionally, the stock soared 37.82% since the start of the year. The stock currently has a market cap of $2.62 billion.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily